Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 4, 2021, the Board of Directors (the "Board") of Mirum Pharmaceuticals, Inc. (the "Company") appointed Carol L. Brosgart, M.D. as a director of the Company. Dr. Brosgart will serve as a Class I director, with an initial term expiring at the Company's 2023 Annual Meeting of Stockholders. Dr. Brosgart will not initially serve on any committees of the Board.

Pursuant to the Company's Non-Employee Director Compensation Policy (as it may be amended from time to time, the "Policy"), Dr. Brosgart was granted a stock option to purchase 34,000 shares of the Company's common stock in connection with her appointment to the Board, which will vest in three equal annual installments measured from the date of grant, subject to Dr. Brosgart's continuous service as of each such date. In addition, in accordance with the Policy, Dr. Brosgart will also receive an annual cash retainer of $40,000 for her Board service, which will be pro-rated for 2021. In addition, commencing with the Company's 2022 Annual Meeting of Stockholders, Dr. Brosgart will be eligible to receive an annual option grant to purchase 17,000 shares of the Company's common stock, subject to her continuous service as of each such date. If Dr. Brosgart is appointed to serve on a committee of the Board, she will be entitled to additional cash compensation under the Policy in connection with such service.

There were no arrangements or understandings between Dr. Brosgart and any other persons pursuant to which she was selected as a director, and there are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission between Dr. Brosgart and the Company required to be disclosed herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 4, 2021, the Company held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 7, 2021, the record date for the Annual Meeting, 30,441,753 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

Proposal 1. Election of Directors

The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:





                                                                             Broker
                                    Votes For        Votes Withheld        Non-Votes
        Laurent Fischer, M.D.        18,252,171             3,612,859        5,202,756
        Patrick Heron                20,083,048             1,781,982        5,202,756
        Niall O'Donnell, Ph.D.       19,910,584             1,954,446        5,202,756

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The final voting results are as follows:





                                                             Broker
                 Votes For    Votes Against   Abstentions   Non-Votes
                 27,058,394        75            9,317         -

--------------------------------------------------------------------------------

Item 8.01 Other Events.

On June 7, 2021, the Company issued a press release announcing the appointment of Dr. Brosgart to the Board. A copy of this press release is furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



               Exhibit No.   Description

               99.1            Press Release dated June 7, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses